Studying irreversible electroporation with immunotherapy for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study looks at people with advanced pancreatic cancer who have already been treated with a procedure called irreversible electroporation (IRE), which uses electric pulses to kill cancer cells, sometimes along with immunotherapy drugs. The goal is to learn more about how well this combination works and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that cannot be removed by surgery (locally advanced).
- You have already received IRE ablation (a treatment that uses electric pulses to destroy cancer cells), either alone or with an immunotherapy drug (anti-PD-1 or anti-PD-L1).
- You are 18 years or older.
- You are generally able to care for yourself (ECOG score 0-2).
- You have medical records and at least 6 months of follow-up imaging data.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This is a research registry that collects information from adults with pancreatic cancer who are treated with an ablation procedure called irreversible electroporation (IRE). It may help doctors better understand which patients benefit from this approach and how the treatment is used in real life.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial tests an experimental cell therapy using immune cells called iNKT cells, which are designed to attack pancreatic cancer. It may be an option for people who have already tried standard treatments and are looking for something new.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.